On September 15, Ascendis Pharma A/S fell 12.23% in regular trading, trading at approximately $233.06 per share, with turnover of $3.0 billion — significantly underperforming the broader Biotechnology sector.

The sharp decline was triggered by the company's announcement that it has terminated a collaboration agreement reached with Novo Nordisk in 2024, regaining exclusive rights to its proprietary TransCon technology platform in metabolic and cardiovascular diseases, including obesity. Alongside the termination, Ascendis disclosed a $400 million share buyback program.

Market concerns center on the loss of commercial synergies with Novo Nordisk, the global leader in GLP-1 therapies. Going forward, Ascendis will need to independently advance its metabolic pipeline through development and commercialization in the highly competitive obesity drug landscape, raising execution risk. Despite solid recent fundamentals — Q2 revenue of $394.4 million beating estimates, strong Yorvipath uptake at 252 million euros, and accelerating Yuviwel enrollment exceeding 220 patients — the strategic shift away from a major partner weighed heavily on sentiment. Analysts had maintained consensus buy ratings with a mean price target of approximately $313 prior to the announcement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)